Bibliography
- Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367(6464):645-8
- Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3(7):730-7
- Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells mask the heterogeneity of leukemia-initiating cells. Blood 2008;112(3):568-75
- Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5(7):738-43
- Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983-8
- Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63(18):5821-8
- Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432(7015):396-401
- Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005;102(19):6942-7
- Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-51
- Lawson DA, Xin L, Lukacs RU, et al. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA 2007;104(1):181-6
- O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445(7123):106-10
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445(7123):111-5
- Kim CFB, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121(6):823-35
- Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67(3):1030-7
- Kondo T. Methods and means related to cancer stem cells. US2008132423; 2008
- Sanchez-Garcia I, Perez-Caro M. Identification of cancer stem cells using genetic markers. WO2008029290; 2008
- Jamieson CH, Geron I, Abrahamson A, et al. WNT pathway mutations in cancer stem cells. WO2008073619; 2008
- Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005;1044:1-5
- Edwards RH, Wasik MA, Finan J, et al. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. Am J Clin Pathol 1999;112(6):819-27
- Asou N. 2. All-trans retinoic acid in the treatment of acute promyelocytic leukemia. Intern Med 2007;46(2):91-3
- Kazuo U, Masahiro K, Yoji U, Yoko I. Therapeutic agent for ATRA-resistant APL. JP2005068080; 2005
- George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 2001;97(12):3925-30
- Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008;319(5861):336-9
- Nilsson L, Astrand-Grundstrom I, Anderson K, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002;100(1):259-67
- Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008;22(6):1207-13
- Szatrowski TP, Dodge RK, Reynolds C, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer 2003;97(6):1471-80
- Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104(7):2204-5
- Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 2002;99(1):319-25
- Holtz MS, Slovak ML. Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99(10):3792-800
- Bandyopadhyay S, Pal BC, Bhattacharya S, et al. A pharmaceutical composition useful for treating chronic myeloid leukemia. WO2004004708; 2004
- Braun K, Waldeck W, Pipkorn R, et al. PNA-conjugates for treating chronic myeloid leukemia (CML). WO03039438; 2003
- Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103(6):2332-6
- Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68(1):190-7
- Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007;104(10):4048-53
- Austad B, Janardanannair S, Lescarbeau A, et al. Methods of use for cyclopamine analogs. WO2008083252; 2008
- Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67(9):4010-5
- Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122(4):761-8
- Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67
- Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756-60
- Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005;307(5717):1904-9
- Marchiano RD. Digestive system cancer stem cells and tests and uses therefor. WO2008034645; 2008
- Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118(6):2111-20
- Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104(24):10158-63
- Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: Strange bedfellows? Am J Respir Crit Care Med 2007;175(6):547-53
- Berns A. Stem cells for lung cancer? Cell 2005;121(6):811-3
- Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15(3):504-14
- Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15(5):193-7
- Ponti D, Zaffaroni N, Capelli C, Daidone MG. Breast cancer stem cells: an overview. Eur J Cancer 2006;42(9):1219-24
- Clarke MG, Morrison SJ, Wicha MA, Al-Hajj M. Isolation and use of solid tumor stem cells. US2007231325; 2003
- Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors [abstract]. Breast Cancer Res 2008;10(3):R53
- Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006;42(9):1213-8
- Burger PE, Xiong X, Coetzee S, et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA 2005;102(20):7180-5
- Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001;114:3865-72
- Richardson GD, Robson CN, Lang SH et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004 117(Pt 16):3539-45
- Maitland N, Collins A. Prostate stem cell. WO2005089043; 2005
- Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25(12):1696-708
- Li JG. Liver-cancer stem cell, its separation and use. CN1940062; 2007
- Ma S, Chan KW, Lee TK, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008;6(7):1146-53
- Wicha M, Dontu G, Ginestier C, et al. Aldehyde dehydrogenase 1(ALDH1) as a cancer stem cell marker. WO2008036419; 2008
- Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008;13(2):153-66
- Monzani E, Facchetti F, Galmozzi E. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential. Eur J Cancer 2007;43(5):935-46
- Dou J, Pan M, Wen P, et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 2007;4(6):467-72
- Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999;94(6):2056-64
- Zhang Y, Zhou J, Zhang H. Use of 8-quinolinol and its analogs to target cancer stem cells. WO2008013966; 2008
- Raaijmakers MH, de Grouw EP, Heuver LH, et al. Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. Clin Cancer Res 2005;11(6):2436-44
- Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451(7176):345-9
- Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 2008;26(5):535-42
- Sung JM, Cho HJ, Yi H, et al. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008;371(1):163-7
- Christgen M, Ballmaier M, Bruchhardt H, et al. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem 2007;306:201-12
- Olempska M, Eisenach PA, Ammerpohl O, et al. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007;6(1):92-7
- Pascal LE, Oudes AJ, Petersen TW, et al. Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol 2007;7:6
- Donnenberg VS, Donnenberg AD. Identification of a constitutively resistant cancer stem cell. WO2007118242; 2007
- Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101(39):14228-33
- Mitsutake N, Iwao A, Nagai K, et al. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007;148(4):1797-803
- Huang D, Gao Q, Guo L. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2008 [Epub ahead of print]
- Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, p-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998;95(12):7024-9
- Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93(3):1075-85
- van Stijn A, van der Pol MA, Kok A, et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003;88(5):497-508
- Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):687-8
- Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67(1):1-5
- Kang MK, Hur BI, Ko MH, et al. Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci 2008;9:15
- Kawabe T, Kobayashi H. Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments. US2008227827; 2008
- Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12(10):1167-74
- Charrad RS, Gadhoum Z, Qi J, et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002;99(1):290-9
- Charrad RS, Li Y, Delpech B, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999;5(6):669-76
- Krause DS, Lazarides K, von Andrian UH, Etten RAV. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006;12(10):1175-80
- Smadja F, Dick JE, Kadouche J. Chimeric anti-CD44 antibodies and their use for treating acute myeloid leukemia. US2007237761; 2007
- Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98(8):2301-7
- Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002;99(25):16220-5
- Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105(11):4163-9
- Crooks PA, Jordan CT, Wei X. Use of parthenolide derivatives as antileukemic and cytotoxic agents. US2005272716; 2005
- Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10(5):375-88
- Yu Q, Tan J, Yang XJ. Methods for cancer therapy and stem cell modulation. WO2007100304; 2007
- Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006;66(9):4553-7
- Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11(1):69-82
- Huntly BJP, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004;6(6):587-96
- Cozzio A, Passegue E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17(24):3029-35
- Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007;26:6766-76
- Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423(6937):255-60
- Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66(12):6063-71
- Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008;452(7187):650-3
- Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441(7092):475-82
- Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006;441:518-22
- Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006;442(7104):818-22
- Krivtsov AV, Armstrong S. Novel signature self renewal gene expression programs. WO2007112097; 2007
- Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30(1):41-7
- Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related ‘self-renewal’ signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26(18):3015-24
- Birnie R, Bryce SD, Roome C, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biology 2008;9:R83
- Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356(3):217-26
- Jordan CT, Guzman ML, Hassane D. Use of gene signatures to design novel cancer treatment regimens. WO2008086182; 2008
- Donnenberg VS, Donnenberg AD. Identification of a constitutively resistant cancer stem cell. WO2007118242; 2007
- Kato J. Method for producing and acquiring cancer stem cell and method for screening antileukemic medicine by targeting the same stem cell. JP2007330205; 2007
- Takakura N, Yamada Y, Kidoya H. Method of producing cancer stem cell. WO2006115243; 2006
- Sanchez-Garcia I, Voces SF. Murine stem cells and applications thereof. EP1726208; 2006
- Robins AJ, Schulz TC. Human cancer stem cell culture compositions comprising ERBB2 variants and methods of use thereof. WO2007147165; 2007
- Scheffler B, Goetz AK, Steindler DA. Isolation, expansion and uses of tumor stem cells. WO2008033393; 2008
- Mazar A. Antibodies to urokinase-type plasminogen activator receptor (uPAR) bind cancer stem cells: use in diagnosis and therapy. WO2007134274; 2007
- Reiter R, Witte O. PSCA: Prostate stem cell antigen for diagnosis and treatment of prostate cancer. NZ516660; 2003
- Donnenberg VS, Donnenberg AD. constitutively resistant cancer stem cells in diagnosis. WO2007118238; 2007
- Laird P, Widschwendter M. DNA methylation markers based on epigenetic stem cell signatures in cancer. WO2008083251; 2008
- Cirrito T, Bergstein I. Cancer therapy with cantharidin and cantharidin analogs. WO2008030617; 2008
- Cirrito T, Bergstein I. Cancer stem cell-targeted cancer therapy. WO2008030538; 2008
- Yu J. Cancer stem cell antigen vaccines and methods. WO2008039874; 2008
- Gurney A, Sato A, Fitch-Bruhns M. Compositions and methods for diagnosing and treating cancer. WO2008091641; 2008
- Lewicki J, Gurney A, Satyal S. Compositions and methods for diagnosing and treating cancer. WO2008070090; 2008
- Philip R, Keller LH. Immunogens in cancer stem cells. WO2008070047; 2008
- Yu Q, Tan J, Yang XJ. Methods for cancer therapy and stem cell modulation. WO2007100304; 2007